Pricing Log in Create free account
Friday 6 November 2026 Export ADPT’s income statement to Excel — free account

Adaptive Biotechnologies Corporation

ADPT Healthcare Diagnostics & Research

Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.

Revenue
−10.7%
EPS
−66.7%
Free cash flow
+201.9%

Quarter to September 2026, against a year earlier

27.54 0.71 +2.65%
Market cap
$4.3B
P/E
0.0×
Fwd P/E
−49.4×
Dividend yield
—
F-score
6/9
Altman Z
2.08
Beneish M
−2.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Adaptive Biotechnologies Corporation (ADPT) EV/Sales

Alert me on EV/Sales

As of 5 November 2026, Adaptive Biotechnologies Corporation (ADPT) trades at a EV/Sales of 14.6×. Over the past ten years it has ranged from −0.3× (September 2019) to 86.6× (December 2020); the current reading is higher than 69% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 8.9× 80.52%
FY2024 4.9× 49.10%
FY2023 3.3× (27.13%)
FY2022 4.5× (81.10%)
FY2021 23.9× (67.20%)
FY2020 72.9× 305.70%
FY2019 18.0× —
FY2018 0.0× —
FY2017 0.0× —

Quarterly newest first

Period EV/Sales Change
Sep 2026 15.7× 41.23%
Jun 2026 11.1× 51.88%
Mar 2026 7.3× (17.57%)
Dec 2025 8.9× (1.98%)
29 more quarters

Against its own ten years

Low −0.3× High 86.6×
Ten-year median 8.2×
Current reading's percentile 69

EV/Sales against peers

Company EV/Sales
VCYT Veracyte, Inc. compare 2.5×
RDNT RadNet, Inc. compare 3.0×
NEO NeoGenomics, Inc. compare 3.3×
WGS GeneDx Holdings Corp. compare 4.2×
SHC Sotera Health Company compare 5.2×
CDNA CareDx, Inc. compare 7.6×
BLLN BillionToOne, Inc. compare 11.0×
ADPT Adaptive Biotechnologies Corporation 14.6×
GRAL GRAIL, Inc. compare 29.8×
Diagnostics & Research industry median 5.2×
Healthcare sector median 3.5×
Market median 2.1×

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on ADPT